We suggest that biomarker-driven or biomarker-stratified trials, followed rapidly by biomarker validation in well-curated, longitudinal, real-world registry studies with existing biobanks or available omics data from tissue and blood, may be a feasible and desirable route to achieving truly patient-centred precision medicine for CYP with arthritis. Here, PPIG is linked to Arthritis.